NCT03314493

Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients

Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Professor Fernando Figueira Integral Medicine Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Vascular calcification is a frequent complication in dialysis patients and is strongly associated with mortality. Its pathogenesis is complex and involves a series of markers that act on the vascular microenvironment. There is evidence that aldosterone is one of the biomarkers and may have a role in osteoinductive pathways.The aim of this study was to evaluate the effect of spironolactone, an inhibitor of mineralocorticoid receptor, in the progression of coronary calcification in patients undergoing peritoneal dialysis.

Conditions

• Coronary Artery Calcification
• Vascular Calcification

Interventions

Type	Name	Description
DRUG	Spironolactone 25Mg Tablet	Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months

Timeline

• Start date: 2014-11-07
• Primary completion: 2016-11-10
• Completion: 2016-11-10
• First posted: 2017-10-19
• Last updated: 2017-10-19

Locations

1 site across 1 country: Brazil